Spironolactone vs Metformin for PCOS: What to Do When One Fails

What Each Drug Actually Does in a Woman with PCOS

These are not interchangeable drugs. They act on entirely different biological targets, and understanding that difference is the fastest way to know which one is failing you and why.

Spironolactone is an aldosterone antagonist that also blocks androgen receptors and mildly suppresses ovarian androgen production. In PCOS, excess testosterone and dihydrotestosterone (DHT) drive acne, oily skin, facial and body hair growth, and androgenic alopecia. Spironolactone competes with these androgens at the receptor level, so even if serum testosterone stays elevated, the end-organ sees less signal.

Metformin works upstream. It reduces hepatic glucose production, improves peripheral insulin sensitivity, and lowers circulating insulin. In PCOS, high insulin stimulates ovarian theca cells to overproduce androgens, so bringing insulin down can lower testosterone indirectly and restore more regular ovulation. Metformin does not block androgen receptors directly.

The Two Dominant PCOS Phenotypes and Which Drug Fits Each

The 2023 International Evidence-based PCOS Guideline identifies four Rotterdam phenotype combinations. For practical prescribing, most clinicians group women into two broad patterns:

Androgen-dominant PCOS. Elevated free testosterone or DHEA-S, normal or mildly elevated fasting insulin, normal BMI or mild overweight, primary complaints of acne, hirsutism, or hair loss. This pattern responds better to spironolactone.

Metabolic/insulin-resistant PCOS. Elevated fasting insulin, elevated HOMA-IR, irregular cycles, difficulty losing weight, elevated triglycerides, or impaired fasting glucose. This pattern responds better to metformin. The Cochrane review of metformin in PCOS (44 trials, 4,521 women) found metformin improved clinical pregnancy rates and ovulation frequency versus placebo, particularly in women with insulin resistance.

Many women have both patterns. That is when combination therapy becomes relevant, covered below.

What "Failure" Looks Like for Each Drug

Spironolactone failure is defined as persistent moderate-to-severe hirsutism (Ferriman-Gallwey score above 8), ongoing cystic acne requiring ongoing topical or oral antibiotics, or hair loss progressing after six months at an adequate dose (at least 100 mg/day). A dose below 75 mg/day is often a dosing failure, not a drug failure.

Metformin failure is defined as persistent anovulation (fewer than eight cycles per year) after three to six months at a therapeutic dose (at least 1500 mg/day), no improvement in fasting insulin or HOMA-IR, or continued weight gain despite adherence and lifestyle modification.

Spironolactone for PCOS: Evidence, Dosing, and What to Expect

The 2015 Cochrane review of anti-androgens for hyperandrogenism in PCOS analyzed 22 trials in 1,496 women and found spironolactone significantly reduced Ferriman-Gallwey hirsutism scores compared to placebo (mean difference -7.2 points). That is a clinically meaningful reduction, roughly equivalent to moving from "moderate" to "minimal" body hair. Spironolactone also outperformed metformin head-to-head for hirsutism in multiple included trials.

Standard Dosing in Women

Most clinicians start at 50-100 mg/day and titrate to 100-200 mg/day based on response and tolerability. The FDA-approved indication for spironolactone is hypertension and edema, not PCOS or hirsutism. Use in PCOS is off-label. That does not make it inappropriate. Every major PCOS guideline, including guidance cited by ACOG, endorses it as a first-line anti-androgen for hyperandrogenism symptoms when oral contraceptives (OCs) alone are insufficient.

Is Spironolactone Always Combined with an Oral Contraceptive?

Classically, yes. Spironolactone can cause irregular bleeding by disrupting aldosterone-driven cycle regulation, and its antiandrogenic action during a pregnancy would feminize a male fetus (see the Pregnancy section below). An OC provides cycle control, adds its own anti-androgen effect (particularly with drospirenone- or cyproterone-containing pills where available), and prevents pregnancy.

Some clinicians prescribe spironolactone alone in women who cannot tolerate OCs, are postmenopausal with PCOS features, or have reliable non-hormonal contraception with no desire for pregnancy. This requires close monitoring and documented contraceptive planning.

Who Gets the Best Response

Women with elevated free testosterone, clear clinical hyperandrogenism (acne, hirsutism, or alopecia), and no significant insulin resistance tend to respond best. If your free testosterone is in the upper quartile of the female range or above, and your HOMA-IR is below 2.5, spironolactone is likely the stronger starting drug for you.

Metformin for PCOS: Evidence, Dosing, and What to Expect

The Cochrane metformin-in-PCOS review (2018, 44 RCTs, 4,521 women) concluded that metformin improves ovulation rates, menstrual regularity, and clinical pregnancy rates compared with placebo, but showed less consistent benefit for hirsutism or acne. The pregnancy rate finding matters: for women with PCOS who want to conceive, metformin is the only one of these two drugs that can be continued into early pregnancy if needed.

Dosing and Formulation

Metformin extended-release (ER) causes significantly less nausea and diarrhea than immediate-release at equivalent doses. Starting at 500 mg once daily with the evening meal and increasing by 500 mg every one to two weeks to a target of 1500-2000 mg/day minimizes GI side effects. The therapeutic threshold for ovulation improvement in PCOS appears to be at least 1500 mg/day in most studies.

What Metformin Does and Does Not Improve

| Outcome | Metformin | Spironolactone | |---|---|---| | Menstrual regularity | Moderate improvement | Mild improvement (mainly via OC co-prescription) | | Ovulation rate | Improved vs placebo | Not studied for ovulation directly | | Hirsutism | Minimal effect | Significant reduction | | Acne | Minimal effect | Significant reduction | | Fasting insulin / HOMA-IR | Significant reduction | No direct effect | | Body weight | Small reduction (1-2 kg) | No direct effect | | Lipid profile | Modest improvement | No direct effect |

Women with PCOS and impaired fasting glucose, metabolic syndrome, or a family history of type 2 diabetes get a secondary metabolic benefit from metformin that spironolactone cannot provide.

Life Stage Matters for Metformin

Reproductive years (trying to conceive). Metformin can improve ovulation enough to achieve spontaneous conception in some women with PCOS. The 2018 Cochrane review found metformin increased clinical pregnancy rates (RR 1.93, 95% CI 1.42-2.64) versus placebo. ASRM recommends metformin as one option for ovulation induction in PCOS.

Perimenopause. PCOS does not disappear at midlife. Androgen excess often mellows, but insulin resistance worsens as estrogen falls. Metformin's metabolic benefits may become more important in perimenopausal women with PCOS who develop worsening fasting glucose or new-onset metabolic syndrome.

Pregnancy, Lactation, and Contraception: What You Must Know Before Choosing

This section is required reading. Both drugs carry distinct pregnancy implications, and your choice may need to change the moment conception is a possibility.

Spironolactone: Stop Before Trying to Conceive

Spironolactone is classified as potentially teratogenic based on animal studies showing feminization of male fetuses. Human data are limited but concerning enough that every major clinical body recommends stopping spironolactone before attempting pregnancy. There is no established safe window of exposure in the first trimester.

Practical rule: Stop spironolactone at least one full menstrual cycle (ideally two cycles) before discontinuing contraception. Because PCOS cycles can be unpredictable, use reliable contraception throughout the entire course of spironolactone treatment.

Lactation data are sparse. Spironolactone and its active metabolite canrenone are detectable in breast milk at low levels. The American Academy of Pediatrics considers it likely compatible with breastfeeding given the low relative infant dose, but most clinicians recommend discussing risk-benefit with a lactation medicine specialist before continuing postpartum.

Metformin: More Flexibility, but Not Risk-Free

Metformin crosses the placenta. It has been used in PCOS pregnancies, particularly in women with type 2 diabetes or significant insulin resistance, and has not been linked to major congenital malformations in human observational data. The ACOG guidance on PCOS notes that metformin is sometimes continued in the first trimester in women with insulin-resistant PCOS to reduce miscarriage risk, though evidence for miscarriage prevention is not definitive.

Metformin passes into breast milk in small amounts. Infant exposure is approximately 0.28% of the weight-adjusted maternal dose, considered low. Most lactation guidelines consider metformin compatible with breastfeeding.

Contraception requirement: Metformin may restore ovulation in previously anovulatory women. If you are not trying to conceive, restoring ovulation means you can now get pregnant. Use reliable contraception when starting metformin for PCOS if pregnancy is not your goal.

When Spironolactone Fails: Your Specific Next Steps

"Failure" is not the same across all women. Before switching entirely, rule out the following:

Step 1. Confirm the Dose Was Adequate

Many women are started on 25-50 mg/day and never titrated up. The evidence for hirsutism reduction in the Cochrane review reflects doses of 100-200 mg/day. If you have been on 50 mg/day for six months without improvement, ask about titrating to 100-150 mg/day before declaring the drug a failure.

Step 2. Check Whether Insulin Resistance Is the Hidden Driver

If your labs show elevated fasting insulin (above 12-15 mIU/L fasting), elevated HOMA-IR (above 2.5), or high triglycerides with low HDL, your ovaries may be secreting excess androgens driven by insulin signaling that spironolactone cannot interrupt at the receptor level. In that scenario, adding metformin may reduce androgen production upstream, making spironolactone more effective at the receptor, even if neither drug alone was sufficient. This combination is supported by clinical practice guidelines cited in the 2018 ACOG PCOS bulletin.

Step 3. Rule Out an Alternative Androgen Source

Persistent hyperandrogenism despite adequate spironolactone warrants labs to exclude late-onset congenital adrenal hyperplasia (check 17-hydroxyprogesterone), an androgen-secreting ovarian or adrenal tumor (testosterone >150 ng/dL warrants imaging), or Cushing syndrome. These are not PCOS and will not respond to either drug.

Step 4. Genuine Spironolactone Failure: What to Switch To

If the dose was adequate, insulin resistance has been excluded or treated, and alternative causes have been ruled out, you have several options:

• Add metformin if insulin resistance is co-present (combination approach).
• Switch to a higher-androgen-potency OC with cyproterone acetate (where available outside the US) or drospirenone.
• Add finasteride 2.5-5 mg/day for androgenic alopecia specifically. Finasteride blocks 5-alpha-reductase, reducing DHT conversion, and works in a complementary pathway to spironolactone's receptor blockade. Finasteride is also teratogenic and requires reliable contraception.
• Discuss eflornithine cream for facial hirsutism as a topical adjunct.

When Metformin Fails: Your Specific Next Steps

Step 1. Confirm the Dose and Formulation

Doses below 1500 mg/day are often inadequate for ovulation induction in PCOS. If you have been on 500-1000 mg/day and had poor GI tolerance, switching to metformin ER (extended-release) taken with the largest meal of the day substantially reduces side effects. The therapeutic dose for cycle regulation is 1500-2000 mg/day in most clinical studies.

Step 2. Assess What Metformin Was Supposed to Fix

If metformin was prescribed primarily for acne or hirsutism and those symptoms have not improved, that is not metformin failure. That is a mismatch between drug mechanism and symptom target. Spironolactone directly addresses androgen-driven skin and hair symptoms. Adding it is the appropriate next step, not abandoning metformin.

If metformin was prescribed for cycle regulation and ovulation and cycles remain severely irregular after three to six months at a therapeutic dose, your clinician may consider:

• Adding letrozole as an ovulation induction agent. The NEJM 2014 PPCOSII trial showed letrozole 2.5-7.5 mg/day (cycle days 3-7) produced higher live birth rates than clomiphene in women with PCOS. Letrozole does not replace metformin but is used alongside it when spontaneous ovulation is the goal.
• Adding inositol (myo-inositol) as an adjunct. Evidence is mixed but a Cochrane-adjacent systematic review suggests myo-inositol may improve insulin sensitivity and ovulation in some women with PCOS, with a favorable safety profile.
• Reassessing lifestyle factors before declaring pharmacologic failure. A 5-10% reduction in body weight through diet and exercise improves insulin sensitivity and ovulation rates independent of any medication.

Step 3. Persistent Anovulation Despite Combination Therapy

If metformin plus lifestyle modification plus letrozole fails to achieve ovulation, referral to a reproductive endocrinologist for gonadotropin stimulation or IVF assessment is appropriate. This is not a personal failure. PCOS is a heterogeneous condition with a spectrum of insulin resistance severity.

Who This Approach Is Right For (and Who It Is Not)

Spironolactone Is a Good Fit If You

• Have confirmed androgen excess (elevated free testosterone, DHEA-S, or clinical signs of hirsutism/acne/alopecia)
• Are not planning pregnancy in the near term and are using reliable contraception
• Have normal or mildly elevated insulin levels
• Have tried OCs alone with inadequate acne or hirsutism control

Spironolactone Is Not the Right Choice If You

• Are actively trying to conceive or may become pregnant without planning
• Are pregnant (contraindicated)
• Have significant renal impairment (potassium retention risk)
• Have hyperkalemia or are on ACE inhibitors or ARBs without close monitoring

Metformin Is a Good Fit If You

• Have insulin resistance confirmed by fasting labs or HOMA-IR
• Have irregular cycles, anovulation, or are trying to conceive
• Have pre-diabetes or a strong family history of type 2 diabetes
• Are perimenopausal with worsening metabolic markers alongside residual PCOS

Metformin Is Not the Right Choice If You

• Have normal insulin sensitivity and your primary complaints are acne and hirsutism
• Have eGFR <30 mL/min/1.73m² (contraindicated due to lactic acidosis risk)
• Have a history of metformin-associated B12 deficiency without supplementation in place

The Evidence Gap: What We Do Not Yet Know

Women have been under-represented in many metabolic and endocrine trials. Most PCOS drug trials are short (three to six months), small (fewer than 200 participants), and use surrogate endpoints like Ferriman-Gallwey scores or hormone levels rather than patient-reported outcomes like quality of life, sexual function, or mood.

The 2015 Cochrane anti-androgen review noted that most included trials were of low to moderate quality, with significant heterogeneity in dosing, comparators, and outcome measurement. The 2018 Cochrane metformin review similarly flagged that live birth rate data were limited and pregnancy safety data were incomplete. What this means for you: the evidence supports using both drugs, but the fine-grained personalization about exactly when to switch, at what dose, and for how long is still guided largely by clinical experience rather than head-to-head trials in large, diverse female populations.

Perimenopausal women with PCOS are especially under-studied. Most trials enroll women aged 18-40. If you are 44 with residual PCOS symptoms and worsening insulin resistance as estrogen declines, your clinician is making educated, evidence-informed decisions, but the specific trial data for your demographic is thin. Ask about that directly. A clinician who admits the evidence is limited is more trustworthy than one who is not.

Monitoring: Labs to Track Whichever Drug You Choose

On Spironolactone

• Serum potassium at baseline, six weeks, and then every six months (aldosterone blockade raises potassium)
• Blood pressure (spironolactone can lower it; hypotension risk in lean women)
• Free testosterone and DHEA-S at baseline and six months to confirm androgen suppression
• Ferriman-Gallwey score every three to six months (clinical response marker)

On Metformin

• Fasting glucose, HbA1c, and fasting insulin at baseline and every six months
• Renal function (eGFR) at baseline and annually (metformin is renally cleared)
• Serum B12 annually. Metformin reduces B12 absorption by approximately 22% over two to four years; deficiency can cause peripheral neuropathy
• Menstrual calendar to document cycle regularity